HomeMBIO • NASDAQ
add
Mustang Bio Inc
Previous close
$1.29
Day range
$1.26 - $1.30
Year range
$1.01 - $65.00
Market cap
5.60M USD
Avg Volume
764.10K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Market news
Financials
Income Statement
Revenue
Net income
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 253.00K | -95.16% |
Net income | -153.00K | 97.05% |
Net profit margin | — | — |
Earnings per share | — | — |
EBITDA | -219.00K | 95.57% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 14.23M | 964.40% |
Total assets | 14.91M | 2.17% |
Total liabilities | 11.30M | -42.16% |
Total equity | 3.61M | — |
Shares outstanding | 4.38M | — |
Price to book | 1.21 | — |
Return on assets | -5.22% | — |
Return on capital | -206.03% | — |
Cash Flow
Net change in cash
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Net income | -153.00K | 97.05% |
Cash from operations | -1.39M | 73.90% |
Cash from investing | 1.16M | — |
Cash from financing | 7.62M | 15,442.86% |
Net change in cash | 7.39M | 240.21% |
Free cash flow | -31.12K | 99.05% |
About
Mustang Bio is an American clinical-stage biopharmaceutical company founded in 2015 and headquartered in Worcester, MA, U.S. Operating as a partner company of Fortress Biotech, Mustang Bio develops CAR-T immunotherapies and gene therapies for multiple diseases, including hematologic cancers, solid tumors, and X-linked severe combined immunodeficiency. Wikipedia
Founded
2015
Headquarters
Website
Employees
6
